Recent clinical trials have demonstrated excellent safety profiles using in vivo CRISPR/Cas9 editing of the KLKB1 gene to treat patients with hereditary angioedema and editing the HSV-1 gene to treat patients with herpetic stromal keratitis [130,131]. The gene discussed is KLKB1; the disease is hereditary angioedema.